A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433
Latest Information Update: 03 Jul 2024
Price :
$35 *
At a glance
- Drugs Upadacitinib (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms U-ENDURE
- Sponsors AbbVie; AbbVie Germany
- 19 Feb 2024 According to AbbVie Media Release, data from the study will be presented at the 19th Congress of European Crohn's and Colitis Organisation (ECCO) taking place in Stockholm, Sweden from February 21-24.
- 17 Oct 2023 Results of a pooled analysis assessing effect of UPA treatment on extraintestinal manifestations in patients in induction and maintenance studies: U-EXCEL, U-EXCEED and U-ENDURE presented at the 31st United European Gastroenterology Week
- 17 Oct 2023 Results of pooled analysis ( from studies NCT03345849,NCT03345836, and NCT03345823) assessing efficacy and safety of upadacitinib for patients with Crohns disease presented at the 31st United European Gastroenterology Week